Antibody Production Shared Resource

抗体生产共享资源

• 批准号: 8934376
• 负责人: ROBERT H CARNAHAN
• 金额: $ 10.79万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-17 至 2016-04-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8934376
• 关键词: Adherence; Antibodies; Antibody Formation; Antigens; Area; Basic Science; Biological Assay; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cataloging; Catalogs; Clinical; Communities; Consultations; Development; Doctor of Philosophy; Economics; Environment; Europe; Explosion; Funding; Generations; Genetic Recombination; Goals; Growth; Growth Factor; Housing; Human; Human Resources; Hybridomas; In Vitro; Leadership; Malignant Neoplasms; Mission; Modification; Molecular; Molecular Conformation; Monoclonal Antibodies; Organoids; Oryctolagus cuniculus; Price; Process; Production; Protein Isoforms; Proteins; Reagent; Recombinant Antibody; Recombinant Proteins; Research; Research Personnel; Resource Sharing; Resources; Services; Specificity; Stream; Technology; Therapeutic; Universities; Validation; abstracting; antibody engineering; anticancer research; assay development; base; cost; cost effective; cost efficient; cytokine; design; experience; infrastructure development; innovation; meetings; novel; polyclonal antibody; professor; tool

BASIC RESEARCH GROUP CORE 003 – ANTIBODY PRODUCTION SHARED RESOURCE PROJECT SUMMARY/ABSTRACT Over the past two decades the view of monoclonal antibody utility has grown from valuable scientific reagents to include exciting and potent therapeutics. Over thirty monoclonal antibody–based therapies are now approved for human use in the U.S. and Europe, with nearly one-half of these therapeutics directed at cancer- relevant targets. In cancer research, the value of high-quality antibody reagents is impossible to overstate. A preponderance of molecular assays partially or completely depend upon the function of highly specific antibodies. Though there has been an explosion of commercially available antibodies, considerable variability remains in the actual specificity and utility of many of these reagents. Moreover, as research continues to progress, increasingly more challenging antibody needs continue to emerge (modification-specific antibodies, conformation- and isoform-specific antibodies, functional neutralizing or activating antibodies, etc.). For these reasons, the Vanderbilt-Ingram Cancer Center (VICC) has continuously maintained and supported a vibrant antibody development infrastructure. The Antibody Production Shared Resource (APSR) provides a full range of services supporting all manner of antibody-related projects (polyclonals, monoclonals, recombinant antibodies and antibody engineering, etc.). In addition to making antibodies, the APSR has continued to expand its suite of protein production services to include both antigens and customized functional recombinant proteins (e.g., growth factors, cytokines, etc.). This service is very cost efficient, has opened yet more tools for VICC researchers to obtain valuable reagents and has already successfully delivered critical recombinant proteins at a fraction of the commercial price. This robust suite of protein production and purification capabilities, along with our hybridoma services, provides unique capabilities for the VICC investigators. The proposed additions of in-house rabbit monoclonal antibody development, antibody humanization, and offering an expanded antibody and protein reagent catalog will further add to the technological and economic benefits this facility offers to VICC researchers.

基础研究小组 核心003 - 抗体生产共享资源 项目摘要/摘要 在过去的二十年中 包括令人兴奋的潜在疗法。现在已经有30多个单克隆抗体的疗法 在美国和欧洲被批准用于人类使用，其中将近一半针对癌症 相关目标。在癌症研究中，高质量抗体试剂的价值不可能夸大其词。一个 分子测定的优势部分或完全取决于高度特异性的功能 抗体。尽管商业上可用的抗体爆炸了，但可变性很大 仍然存在着许多这些试剂的实际特异性和效用。而且，随着研究的继续 进步，越来越多的挑战者抗体需要继续出现（修饰特异性抗体， 构象和同工型特异性抗体，功能中和或激活抗体等）。为此 原因，范德比尔特 - 伊吉拉姆癌症中心（VICC）一直保持并支持充满活力 抗体开发基础设施。抗体生产共享资源（APSR）提供了全范围 支持各种抗体相关项目的服务（多克隆，单克隆，重组 抗体和抗体工程等）。除了制作抗体外，APSR还继续 将其蛋白质生产服务的套件扩展到包括抗原和定制功能重组 蛋白质（例如生长因子，细胞因子等）。这项服务非常成本效率，已经为此开了更多的工具 VICC研究人员获得有价值的试剂，并已经成功地提供了关键的重组 蛋白质仅占商业价格的一小部分。这款稳健的蛋白质生产和纯化套件 功能以及我们的杂交瘤服务，为VICC调查人员提供了独特的功能。这 拟议的内部兔子单克隆抗体开发，抗体人性化和发行的添加 扩展的抗体和蛋白质试剂目录将进一步增加技术和经济利益 该设施为VICC研究人员提供了。